Gilead Sciences chairman and CEO Daniel O’Day joins 'Squawk Box' to discuss the FDA approval of the company's HIV prevention ...

Gilead Sciences Inc. closed 11.48% below its 52-week high of $119.96, which the company reached on March 10th.

Gilead Sciences (NASDAQ:GILD) has demonstrated a strong performance this year, with its stock up 18% compared to the S&P ...

Gilead Sciences’ first quarter performance saw sales remain flat year over year, which did not meet Wall Street’s revenue ...

WASHINGTON — The U.S. has approved the world’s only twice-a-year shot to prevent HIV, the first step in an anticipated global ...

The National Institutes of Health office responsible for issuing federal guidelines related to treatment of HIV and AIDS ...

Gilead's CEO says he's committed to making sure people around the world can get his firm's new HIV prevention shot Yeztugo.

Gilead is now waiting for regulatory decisions on the twice-yearly PrEP in Europe and other markets, including South Africa ...

Gilead has won FDA approval for an HIV prevention shot that is administered only once every six months. When will low-income ...

With the FDA’s much-anticipated nod for Gilead Sciences’ long-acting HIV pre-exposure prophylaxis (PrEP) injection Yeztugo ...

In two recent studies, this new shot reportedly nearly eliminated new infections in people at substantial risk of HIV.

Gilead Sciences Inc. said it won US approval for a drug to prevent HIV that only has to be given twice a year, making it a ...